Pictet Asset Management Holding SA Sells 17,018 Shares of DaVita Inc. $DVA

Key Points

• Pictet Asset Management Holding SA reduced its stake in DaVita by 69.2%, selling 17,018 shares in Q4 and finishing the period with 7,558 shares valued at $859,000.
• DaVita beat Q1 estimates (adjusted EPS $2.87 vs. $2.33 est.; revenue $3.42B) and raised FY2026 adjusted EPS guidance to 14.10–15.20, prompting a rally and continued share buybacks.
• Despite the upbeat results, analyst coverage is mixed — the consensus rating is a Hold with an average price target of $166.50 — and notable institutional/insider selling remains a potential headwind.

Pictet Asset Management Holding SA lowered its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 69.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,558 shares of the company's stock after selling 17,018 shares during the period. Pictet Asset Management Holding SA's holdings in DaVita were worth $859,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Elevation Wealth Partners LLC raised its stake in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the second quarter valued at $43,000. iSAM Funds UK Ltd bought a new position in DaVita during the third quarter worth $46,000. Stance Capital LLC bought a new position in DaVita during the third quarter worth $47,000. Finally, Smartleaf Asset Management LLC raised its stake in DaVita by 34.9% during the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company's stock worth $59,000 after buying an additional 117 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of analyst reports. Zacks Research downgraded shares of DaVita from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 6th. UBS Group lifted their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a "buy" rating in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a "hold" rating to a "buy" rating and lifted their target price for the stock from $126.00 to $220.00 in a research note on Wednesday. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Finally, TD Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of "Hold" and an average price target of $166.50.

DaVita News Summary

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 beat: DaVita reported adjusted EPS of $2.87 and revenue of $3.42B, topping consensus and showing year‑over‑year revenue growth and margin expansion — a key driver of the rally. DaVita Inc. 1st Quarter 2026 Results
• Positive Sentiment: Guidance raise: Management lifted FY2026 adjusted EPS guidance to a range of 14.100–15.200, slightly above/consistent with street expectations — this reduces uncertainty on full‑year profits and supports multiple expansion. DaVita lifts annual profit forecast
• Positive Sentiment: Capital returns and investor confidence: Company disclosed ongoing buybacks (repurchases during the quarter and additional repurchases through May 5), which supports EPS and investor sentiment; unusual option activity (large call volume) indicates bullish positioning. Quiver Quantitative analysis
• Neutral Sentiment: Investor access — management participation at BofA Healthcare Conference (May 12) gives investors another venue for guidance color and Q&A; could further influence sentiment depending on commentary. DaVita to Participate in BofA 2026 Health Care Conference
• Neutral Sentiment: Analyst activity: Deutsche Bank reiterated/issued a Buy and set a higher $220 target while other houses vary — positive analyst commentary can reinforce gains but coverage is mixed. Quiver Quantitative analysis
• Negative Sentiment: Institutional/insider selling: Large institutional reductions and notable insider sales (including past sales by Berkshire-related positions) are a potential headwind if sustained. Quiver Quantitative analysis
• Negative Sentiment: Profitability metrics mixed: despite margin improvement, some metrics (reported negative historical ROE) and reliance on reimbursement dynamics remain longer‑term risks investors may reassess after the initial rally. MarketBeat DVA profile

DaVita Trading Up 22.6%

NYSE:DVA opened at $192.49 on Thursday. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 0.55 and a beta of 0.84. The firm has a fifty day simple moving average of $152.12 and a two-hundred day simple moving average of $132.20. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $194.29.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 325.68%. The business's quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the company posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 14.16 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.